We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

52 hedge funds and large institutions have $16.6M invested in Oramed Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more call options, than puts

Call options by funds: $26K | Put options by funds: $4K

0.01% more ownership

Funds ownership: 19.02% → 19.03% (+0.01%)

7% less funds holding

Funds holding: 56 → 52 (-4)

10% less capital invested

Capital invested by funds: $18.6M → $16.6M (-$1.92M)

17% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 18

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
52
Holders Change
-4
Holders Change %
-7.14%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
4
Increased
15
Reduced
18
Closed
8
Calls
$26K
Puts
$4K
Net Calls
+$22K
Net Calls Change
+$31K

Top Buyers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
+$869K
2
RC
RBF Capital
California
+$99.1K
3
PLC
Peapod Lane Capital
New York
+$57.6K
4
SG Americas Securities
SG Americas Securities
New York
+$54.1K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$51K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$179K
2
Citadel Advisors
Citadel Advisors
Florida
-$167K
3
RG
Rathbones Group
United Kingdom
-$122K
4
Two Sigma Investments
Two Sigma Investments
New York
-$106K
5
MAM
Marquette Asset Management
Minnesota
-$80.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
NEWAS
26
N.E.W. Advisory Services
Wisconsin
$40.4K +$15.1K +6,540 +53%
SCM
27
Sage Capital Management
New Jersey
$35.8K – – –
LPL Financial
28
LPL Financial
California
$29.9K -$7.95K -3,446 -20%
Wealth Enhancement Advisory Services
29
Wealth Enhancement Advisory Services
Minnesota
$29.5K – – –
PCM
30
Prelude Capital Management
New York
$28.8K -$692 -300 -2%
Barclays
31
Barclays
United Kingdom
$28.2K – – –
GJIA
32
Glass Jacobson Investment Advisors
Maryland
$25.5K – – –
AS
33
Altshuler Shaham
Israel
$25.4K – – –
CAM
34
Close Asset Management
United Kingdom
$25K +$635 +275 +2%
SPIA
35
Steward Partners Investment Advisory
New York
$18.9K – – –
Simplex Trading
36
Simplex Trading
Illinois
$15K +$7.82K +3,387 +88%
Osaic Holdings
37
Osaic Holdings
Arizona
$9.73K -$3.23K -1,400 -24%
Group One Trading
38
Group One Trading
Illinois
$7.08K +$7.41K +3,210 +3,210%
HNB
39
Huntington National Bank
Ohio
$6.42K +$6.92K +3,000 +150,000%
MCM
40
MAI Capital Management
Ohio
$4.4K +$4.74K +2,055 New
National Bank of Canada
41
National Bank of Canada
Quebec, Canada
$4.24K -$1.15K -500 -20%
FHA
42
First Horizon Advisors
Tennessee
$3.75K +$4.04K +1,750 New
SS
43
SBI Securities
Japan
$3.5K -$12 -5 -0.3%
Northwestern Mutual Wealth Management
44
Northwestern Mutual Wealth Management
Wisconsin
$3.37K – – –
ME
45
McIlrath & Eck
Washington
$2.14K – – –
TRCT
46
Tower Research Capital (TRC)
New York
$1.39K -$4.61K -1,996 -75%
Jones Financial Companies
47
Jones Financial Companies
Missouri
$1.1K -$1.32K -572 -53%
IA
48
IFP Advisors
Florida
$1.07K – – –
GSWM
49
Golden State Wealth Management
California
$648 – – –
BCMLT
50
Beacon Capital Management LLC (Tennessee)
Tennessee
$469 – – –
1
2
3

ORMP Hedge Fund Activity: Q1 2025 in Review

52 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2025, worth a combined $16.6M — down 10% from $18.6M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ORMP and 4 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 15 added.

The largest buyer was BML Capital Management, adding an estimated $869K. The largest seller was UBS Group, cutting an estimated $179K.

  • 52 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2025, down from 56 in Q4 2024.
  • Funds reported $16.6M of Oramed Pharmaceuticals stock for Q1 2025, down 10% quarter-over-quarter.
  • 4 funds opened new Oramed Pharmaceuticals positions in Q1 2025 and 8 closed out, a net change of -4 holders.
  • The largest Oramed Pharmaceuticals buyer in Q1 2025 was BML Capital Management, an estimated $869K added.
  • The largest Oramed Pharmaceuticals seller in Q1 2025 was UBS Group, an estimated $179K sold.

Based on aggregated 13F filings for Q1 2025.